|Title:||Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus||Authors:||Valerón, Pino Fuente
De Pablos-Velasco, Pedro L.
|Issue Date:||2013||Publisher:||0025-7753||Journal:||Medicina Clínica||Abstract:||In this study, we review the efficacy and safety limitations of insulin-dependent oral antidiabetic agents. In terms of efficiency, the main drawback of metformin, sulfonylureas, gliptins and -to a lesser extent-glitazones is durability. No drug per se is able to maintain stable blood glucose control for years. Metformin, sulfonylureas and gliptins have demonstrated safety. Experience with the first two drug groups is more extensive. The main adverse effect of metformin is gastrointestinal discomfort. Major concerns related to the use of sulfonylureas are hypoglycemia and weight gain. The use of pioglitazone has been associated with an increased risk of bladder cancer, edema, heart failure, weight gain, and distal bone fractures in postmenopausal women. The most common adverse reactions associated with glucagon-like peptide-1 agonists are gastrointestinal discomfort that sometimes leads to treatment discontinuation. © 2013 Elsevier España, S.L. All rights reserved.||URI:||http://hdl.handle.net/10553/49727||ISSN:||0025-7753||DOI:||10.1016/S0025-7753(13)70059-9||Source:||Medicina Clinica[ISSN 0025-7753],v. 141, p. 20-25|
|Appears in Collections:||Artículos|
checked on Jun 26, 2022
checked on Jun 4, 2022
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.